Nature Reviews. Drug Discovery最新文献_第9页

Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus 本迪布焦病毒引起的埃博拉的治疗和预防战略。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-06-04 DOI: 10.1038/d41573-026-00094-6

Jean B. Nachega, Jean-Jacques Muyembe-Tamfum, Alimuddin Zumla

引用次数: 0

Inhibiting Nipah virus 抑制尼帕病毒。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-06-03 DOI: 10.1038/d41573-026-00092-8

Sarah Crunkhorn

引用次数: 0

Understanding Ras inhibitor resistance 了解Ras抑制剂耐药性。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-06-03 DOI: 10.1038/d41573-026-00091-9

Sarah Crunkhorn

引用次数: 0

Towards mRNA therapeutics 2.0 迈向mRNA疗法2.0。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-06-03 DOI: 10.1038/s41573-026-01459-7

Kenneth R. Chien, Kylie S. Foo, Nevin Witman

{"title":"Towards mRNA therapeutics 2.0","authors":"Kenneth R. Chien, Kylie S. Foo, Nevin Witman","doi":"10.1038/s41573-026-01459-7","DOIUrl":"10.1038/s41573-026-01459-7","url":null,"abstract":"mRNA technology, which has enabled the rapid development of vaccines for infectious diseases, also holds great promise for a new generation of therapies for a host of rare and common diseases. A decade of clinical trials are beginning to clarify the key barriers to unlock the transformative potential of mRNA drugs, which are being addressed with novel interdisciplinary technical advances that, in some cases, are integrating the fields of gene, cell and mRNA therapies. Here, we review the scientific insights from a select group of clinical studies on mRNA-based drugs, including enzyme replacement therapies for rare diseases, cancer immunotherapies, genome-modifying therapies, and immune cell reprogramming therapies for cancer and autoimmune diseases. Several innovative approaches such as clinically tractable in vivo delivery systems, the development of completely ‘immune-silent’ mRNA–vehicle formulations that allow repeated administration and the development of approaches for preferential delivery to organs other than the liver would expedite the development of mRNA therapeutics 2.0. mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies, which illustrate how technological advances are paving the way for the wider adoption of mRNA technology in drug development.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 10","pages":"757-778"},"PeriodicalIF":91.2,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibiting lactate transport reduces lung fibrosis 抑制乳酸转运可减少肺纤维化。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-06-03 DOI: 10.1038/d41573-026-00090-w

Sarah Crunkhorn

引用次数: 0

Informing HIV vaccine design 为艾滋病毒疫苗设计提供信息。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-06-03 DOI: 10.1038/d41573-026-00093-7

Sarah Crunkhorn

引用次数: 0

Better data for better medicines: a path to data-driven medicines regulation 更好的数据带来更好的药物：数据驱动的药物监管之路。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-05-29 DOI: 10.1038/d41573-026-00083-9

Francois Domergue, Peter Arlett, Emer Cooke, Karl Broich

引用次数: 0

Closing the paediatric gap in cancer drug development: a call to industry. 缩小儿科癌症药物开发的差距：对产业界的呼吁。

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-05-29 DOI: 10.1038/d41573-026-00089-3

Vivek Subbiah, Branko Cuglievan

引用次数: 0

A guide to effective drug development through nonprofit models. 通过非营利模式有效开发药物的指南。

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-05-28 DOI: 10.1038/d41573-026-00088-4

Marc Reichel, Barbara Nasto, Christoph Coch, Martin Steiner, Eva M Murauer, Hubert Trübel

引用次数: 0

Targeting claudins in cancer 靶向癌症中的蛋白质。

IF 91.2 1区医学

Nature Reviews. Drug Discovery Pub Date : 2026-05-28 DOI: 10.1038/s41573-026-01450-2

Yuki Niwa, Shunsuke Matsushita, Izuma Nakayama, Masuo Kondoh

{"title":"Targeting claudins in cancer","authors":"Yuki Niwa, Shunsuke Matsushita, Izuma Nakayama, Masuo Kondoh","doi":"10.1038/s41573-026-01450-2","DOIUrl":"10.1038/s41573-026-01450-2","url":null,"abstract":"Epithelial-derived malignancies account for the majority of human tumours and present considerable treatment challenges owing to their heterogeneity, metastatic potential and resistance to therapy. The claudin family of tetra-transmembrane proteins was identified approximately 28 years ago as containing key regulators of epithelial function. These proteins are integral components of tight junctions, which control barrier integrity, selective channel permeability and cellular organization in epithelial tissues. Subsequent murine studies revealed that claudins also have tissue-specific physiological roles, whereas clinical studies demonstrated that their expression is frequently dysregulated in various cancers, highlighting their potential as therapeutic targets. In the past few decades, increasing efforts to exploit claudins in cancer therapy have led to the development of targeted molecules, including zolbetuximab, a first-in-class CLDN-18.2-targeted antibody for the treatment of gastric cancer, which has been recently approved by the United States Food and Drug Administration. This milestone emphasizes the therapeutic potential of targeting this protein family and its possible role in expanding treatment options for cancer. In this review, we discuss the evolving landscape of claudin-targeting therapeutics, examining key advances, emerging challenges and future prospects. Claudins are emerging as clinically actionable targets in cancer, exemplified by the approval of CLDN-18.2-directed therapy. This review examines the biological basis and therapeutic exploitation of claudins, highlighting diverse targeting modalities and the shift towards leveraging tight junction components as tumour-selective entry points for precision oncology strategies.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 9","pages":"723-738"},"PeriodicalIF":91.2,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0